Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

Summary

Ultragenyx Pharmaceutical released its 2025 Impact Report highlighting the company's commitment to rare disease patients, innovation, and global impact. This is a routine corporate sustainability disclosure with no material clinical, financial, or regulatory implications.